Copyright ©The Author(s) 2021.
World J Gastroenterol. Jun 21, 2021; 27(23): 3279-3289
Published online Jun 21, 2021. doi: 10.3748/wjg.v27.i23.3279
Table 5 Cessation of nucleoside analogues treatment after delivery
APASL 2016[8]EASL 2017[9]AASLD 2018[10]
Cessation of NA therapy (at delivery or 4-12 wk after delivery) is recommended in females without ALT flares and without pre-existing advanced liver fibrosis/cirrhosis. Continuation of NA treatment after delivery may be necessary according to maternal liver disease statusIf NA therapy is given as prophylaxis, i.e., only for the prevention of perinatal transmission, its duration is not well defined (stopping at delivery or within the first 3 mo after delivery)HBV-infected pregnant women who are not on antiviral therapy as well as those who stop antiviral at or early after delivery should be monitored closely for up to 6 mo after delivery for hepatitis flares and seroconversion. Long-term follow-up should be continued to assess need for future therapy